From: Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
A3671022 Study
A3671008 Study
Cmax
AUCinf (μg*h/mL)
t1/2
(μg/mL)
(days)
N
42
32
150
Mean
322
104500
19.6
329
112719
19.2
SD
62
32400
5.7
112
40933
5.9